COMMON STOCK PURCHASE WARRANT EVOFEM BIOSCIENCES, INC.Common Stock Purchase Warrant • May 19th, 2021 • Evofem Biosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 19th, 2021 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 22, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Evofem Biosciences, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Evofem Biosciences, Inc. 50,000,000 Shares of Common Stock No Pre-Funded Warrants to Purchase Shares of Common Stock and Warrants to Purchase 50,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • May 19th, 2021 • Evofem Biosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 19th, 2021 Company Industry JurisdictionEvofem Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 50,000,000 shares of common stock (the “Common Stock”), par value $0.0001 per share (the “Firm Shares”), and (b) no pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock at an exercise price of $0.01 per share and (ii) 50,000,000 common stock warrants to purchase 50,000,000 shares of Common Stock (the “Common Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by the Underwriters is set forth opposite its name on Schedule A hereto. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 7,500,000 shares of Common Stock (the “Option Shares”) and/or 7,500,000 Common Warrants to purchase up to an aggregate of 7,500,000 shares of